Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation

Texas Heart Institute Journal

Volumn 42, Issue 1, 2015, Pages 6-15

  Zhu, Wen Gen ^a   Xiong, Qin Mei ^a   Hong, Kui ^a,b  

^a Second Affiliated Hospital of Nan Chang University   (China)

^b Jiangxi Key Laboratory of Molecular Medicine   (China)

Author keywords

Atrial fibrillation complications epide miology; Decision support techniques; Guidelines as topic; Health status indicators; Population surveillance methods; Predictive value of tests; Randomized controlled trials as topic; Risk assessment methods standards; Stroke epidemiology prevention control; Throm boembolism epidemiology prevention control

Indexed keywords

ANTICOAGULATION; BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR FUNCTION; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CLINICAL EVALUATION; HEART ATRIUM FIBRILLATION; HUMAN; INFORMATION PROCESSING; MEDICAL PRACTICE; META ANALYSIS; PRESCRIPTION; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; THROMBOEMBOLISM; ADULT; AGED; ATRIAL FIBRILLATION; CHI SQUARE DISTRIBUTION; COMPLICATION; DECISION SUPPORT SYSTEM; FEMALE; MALE; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; STROKE; VERY ELDERLY; YOUNG ADULT;

ANTICOAGULANT AGENT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOEMBOLISM; YOUNG ADULT;

EID: 84922565782     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: 10.14503/THIJ-14-4353     Document Type: Review

References (30)

1. Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. Heart disease and stroke sta-tistics--2010 update: a report from the American Heart As-sociation [published erratum appears in Circulation 2011;124 (16): e425]. Circulation 2010;121(7):e46-e215.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Ata r D, Hohn-loser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14(10):1385-413.
3. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med 2010;123(6):484-8.
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich M W, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864-70.
5. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 2008; 156(1):57-64.
6. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratif cation for predicting stroke and thrombo-embolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72.
7. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 2011;57(7):831-8.
8. Lopes RD, Crowley MJ, Shah BR, Melloni C, Wood KA, Chatterjee R, et al. Stroke prevention in atrial f ibrillation. U.S. Agency for Healthcare Research and Quality; 2013.
9. Olesen JB, Lip GY, Lane DA, Kober L, Hansen ML, Karasoy D, et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med 2012;125(8):813-26.
10. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33(12):1500-10.
11. McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, Richardson WS. Users’ guides to the medical literature: X XII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA 2000;284(1):79-84.
12. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21(11):1559-73.
13. Aakre CA, McLeod CJ, Cha SS, Tsang TS, Lip GY, Gersh BJ. Comparison of clinical risk stratif ication for predicting stroke and thromboembolism in atrial f ibrillation. Stroke 2014;45 (2):426-31.
14. Abraham JM, Larson J, Chung MK, Curtis AB, Lakshmina-rayan K, Newman JD, et al. Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? Am J Med 2013;126(12):1141-3.
15. Guo Y, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. Int J Cardiol 2013;168(2):904-9.
16. Lin LY, Lee CH, Yu CC, Tsai C T, Lai LP, Hwang JJ, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial f ibrillation--a nationwide database analysis. Atherosclerosis 2011;217(1):292-5.
17. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an antico-agulated atrial fibrillation cohort. Stroke 2010;41(12):2731-8.
18. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342: d124.
19. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011;106(4):739-49.
20. Poli D, Lip GY, Antonucci E, Grifoni E, Lane D. Stroke risk stratif ication in a “real-world” elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol 2011;22 (1):25-30.
21. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial f ibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013;2: e250.
22. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratif ication schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Hae-most 2011;9 (1):39-48.
23. Santos C, Pereira T, Conde J. CHADS2 score in predicting cerebrovascular events: a meta-analysis [in Portuguese]. Arq Bras Cardiol 2013;100 (3):294-301.
24. Ruiz-Nodar JM, Marin F, Roldan V, Valencia J, Manzano-Fernandez S, Caballero L, et al. Should we recommend oral anticoagulation therapy in patients with atrial f ibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score ? Circ Cardiovasc Interv 2012;5(4):459-66.
25. Jover E, Roldan V, Gallego P, Hernandez-Romero D, Valdes M, Vicente V, et al. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed) 2012; 65(7): 627-33.
26. Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 2011;42(6):1768-70.
27. Chen JY, Zhang AD, Lu HY, Guo J, Wang FF, Li ZC. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol 2013;10(3):258-66.
28. Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GY, Dorian P, et al. The CHA2DS2-VASc score identifies those patients with atrial f ibrillation and a CHADS2 score of 1 who is unlikely to benefit from oral anticoagulant therapy. Eur Heart J 2013;34(3):170-6.
29. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial f ibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107(6):1172-9.
30. Piyaskulkaew C, Singh T, Szpunar S, Saravolatz L 2nd, Ros-man H. CHA(2)DS(2)-VASc versus CHADS(2) for stroke risk assessment in low-risk patients with atrial fibrillation: a pilot study from a single center of the NCDR-PINNACLE registry. J Thromb Thrombolysis 2014;37(4):400-3.